Maciej Krzakowski

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna et al. · The Lancet · 2009 · 1.4K citations · Full text

Medicine, Metronomic Therapy, Phase Iii Trial +7

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor–Eliade Ciuleanu, Thomas Brodowicz, Christoph Zielinski et al. · The Lancet · 2009 · 1.1K citations · Full text

Non-small-cell Lung Cancer, Medicine, Cancer Management +6

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck, R. Kaiser, Anders Mellemgaard et al. · The Lancet Oncology · 2014 · 931 citations · Full text

Oncology, Nintedanib Versus Docetaxel, Lume-lung 1 +10

The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

Heinz Ludwig, Simon Van Belle, Peter Barrett‐Lee et al. · European Journal of Cancer · 2004 · 912 citations

Cancer Epidemiology, Medicine, Cancer Management +6

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

Jacques Bonneterre, Beat Thürlimann, J.F.R. Robertson et al. · Journal of Clinical Oncology · 2000 · 839 citations